<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731003</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 08-2-070</org_study_id>
    <nct_id>NCT00731003</nct_id>
  </id_info>
  <brief_title>The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and Irritable Bowel Syndrome (IBS) Patients</brief_title>
  <official_title>The Effect of Serotonergic Modulation on Intestinal Permeability and Visceral Hypersensitivity in Healthy Individuals and IBS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Serotonin, 5-hydroxytryptamin (5-HT), plays an important role in regulating the
      gastrointestinal functions. In this study we will modulate the serotonin system with acute
      tryptophan depletion (ATD) and administration of 5-hydroxytryptophan (5-HTP). ATD is based on
      ingestion of an amino acid drink devoid of the precursor of serotonin and hence caused a
      decreased serotonin level. 5-hydroxy-tryptophan is the direct precursor of serotonin and its
      administration, an increased serotonin level is expected. During these interventions, gut
      permeability and visceral sensitivity will be measured in healthy individuals and patients
      with irritable bowel syndrome, which is characterized by altered permeability and visceral
      hypersensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary aim is to assess intestinal permeability under altered serotonergic conditions by means of sugar permeability test</measure>
    <time_frame>2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess tight junction functionality and serotonin metabolism To assess visceral hypersensitivity under altered serotoninergic conditions To examine biopsy specimens for serotonergic and intestinal permeability parameters in ex vivo circumstances</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATD procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxitriptan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Amino acid mixture with tryptophan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxitriptan</intervention_name>
    <description>100 mg 5-Hydroxytryptophan will be administered orally.</description>
    <arm_group_label>II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Acute tryptophan depletion</intervention_name>
    <description>Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Amino acid drink with tryptophan</intervention_name>
    <description>Amino acid drink with tryptophan, placebo for the ATD procedure</description>
    <arm_group_label>III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo for 5-HTP</description>
    <arm_group_label>IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IBS-patients

        Inclusion criteria:

          1. IBS will be diagnosed according to the Rome III criteria* [35]:

             Recurrent abdominal pain or discomfort at least 3 days per month in the last 3 months
             associated with 2 or more of the following:

               -  Improvement with defecation

               -  Onset associated with a change in frequency of stool

               -  Onset associated with a change in form (appearance) of stool

                    -  Criteria fulfilled for the last 3 months with symptom onset at least 6
                       months prior to diagnosis

                    -  Discomfort means an uncomfortable sensation not described as pain. In
                       pathophysiological research and clinical trails, a pain/discomfort frequency
                       of at least 2 days a week during screening evaluation is an indication for
                       subject's eligibility.

          2. Based on the medical history and previous examination, no other causes for the
             abdominal complaints can be defined.

          3. Age between 18 and 65 years

        Healthy individuals

        Inclusion criteria:

        All subjects will be screened with a standardized psychiatric examination using the mini
        international neuropsychiatric interview (MINI) to determine present psychiatric state.
        General psychological state will be assessed using the 17 item Hamilton depression rating
        scale (HAM-D17), the Dutch version of the symptom checklist (SCL-90) and the hospital
        anxiety and depression rating scale (HADS). The psychiatric evaluation will be carried out
        by a psychiatrist. Volunteers with deviating scores on any topic will be excluded from
        participation.

        Healthy individuals between age 18 and 65 years will be included in the study.

        Exclusion Criteria:

          -  Exclusion criteria for IBS patients:

               1. Severe co-morbidity hindering a rectal barostat procedure, according to the
                  gastroenterologist's perception.

               2. Abdominal surgery, except for uncomplicated appendectomy, laparoscopic
                  cholecystectomy or hysterectomy.

               3. Inability to stop medication that can influence gastrointestinal motility or
                  perception (like loperamide, butylscopolamine, psylliumsead (metamucil),
                  duspatal, metoclopramide, domperidon, erytromycine), or serotonin metabolism
                  (carbidopa) for at least 3 days before tests.

               4. History of psychiatric disorders including use of psychoactive medication or
                  psychological symptomatology, defined as a diagnosis on the MINI, HAM-D17 score
                  above 18, global severity index score on SCL-90 for females ≥150, for males ≥131,
                  or HADS scores ≥ 8. First-degree family members with psychiatric disorders

               5. Administration of investigational drugs in the 180 days prior to the study

               6. Premenstrual syndrome, dieting, pregnancy, lactation

               7. Excessive alcohol consumption (&gt;20 alcoholic consumption per week)

               8. Smoking

               9. Blood donation within 3 months before the study period

              10. Self-admitted HIV-positive state

              11. Irregular day-night rhythm

        Exclusion criteria for healthy individuals:

          1. History of gastrointestinal, psychiatric disorders including use of psychoactive
             medication or psychological symptomatology, defined as a diagnosis on the MINI,
             HAM-D17 score above 18, global severity index score on SCL-90 for females ≥150, for
             males ≥131, or HADS scores ≥ 8 First-degree family members with psychiatric disorders

          2. Use of medication, except oral contraceptives, within 14 days prior to testing

          3. Administration of investigational drugs in the 180 days prior to the study

          4. Previous abdominal surgery (other than uncomplicated appendectomy, laparoscopic
             cholecystectomy and hysterectomy)

          5. Premenstrual syndrome, dieting, pregnancy, lactation

          6. Excessive alcohol consumption (&gt;20 alcoholic consumption per week)

          7. Smoking

          8. Blood donation within 3 months before the study period

          9. Self-admitted HIV-positive state

         10. Irregular day-night rhythm

         11. Severe co-morbidity hindering a rectal barostat procedure, according to the
             gastroenterologist's perception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A AM Masclee, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F Troost, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Keszthelyi D, Troost FJ, Jonkers DM, van Eijk HM, Lindsey PJ, Dekker J, Buurman WA, Masclee AA. Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome. Aliment Pharmacol Ther. 2014 Aug;40(4):392-402. doi: 10.1111/apt.12842. Epub 2014 Jun 18.</citation>
    <PMID>24943480</PMID>
  </results_reference>
  <results_reference>
    <citation>Keszthelyi D, Troost FJ, Jonkers DM, Kruimel JW, Leue C, Masclee AA. Decreased levels of kynurenic acid in the intestinal mucosa of IBS patients: relation to serotonin and psychological state. J Psychosom Res. 2013 Jun;74(6):501-4. doi: 10.1016/j.jpsychores.2013.01.008. Epub 2013 Feb 15.</citation>
    <PMID>23731747</PMID>
  </results_reference>
  <results_reference>
    <citation>Keszthelyi D, Troost FJ, Jonkers DM, van Donkelaar EL, Dekker J, Buurman WA, Masclee AA. Does acute tryptophan depletion affect peripheral serotonin metabolism in the intestine? Am J Clin Nutr. 2012 Mar;95(3):603-8. doi: 10.3945/ajcn.111.028589. Epub 2012 Feb 1.</citation>
    <PMID>22301931</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>November 11, 2014</last_update_submitted>
  <last_update_submitted_qc>November 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>serotonin</keyword>
  <keyword>gut permeability</keyword>
  <keyword>visceral sensitivity</keyword>
  <keyword>irritable bowel syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Tryptophan</mesh_term>
    <mesh_term>5-Hydroxytryptophan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

